Developer docs
API playgroundTry for free, no card

Search company profiles

Peptilogics

Full company profile

uuid0000tjv

Namestring
Peptilogics
Legal namestring
Peptilogics, Inc.
Websiteurl
peptilogics.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics for medical device-related infections, with its lead program PLG0206 (zaloganan) — a first-in-class engineered anti-biofilm peptide — currently enrolling patients in the pivotal Phase 2/3 RETAIN trial for the treatment of periprosthetic joint infection (PJI). The company targets an indication with no approved therapeutics, addressing approximately 45,000 U.S. cases annually where current standard-of-care failure rates reach 40–60% and five-year mortality is 25%. PLG0206 has secured a triple-layered FDA designation stack (Orphan Drug, Fast Track, and Qualified Infectious Disease Product), and the RETAIN trial is planned to enroll up to 240 patients across up to 50 U.S. clinical sites.

The company's discovery engine is the Nautilus™ AI platform, which combines proprietary deep generative models, predictive models, and biophysical simulation for in silico multiparameter optimization of peptide sequences. Nautilus™ is operationally paired with purpose-built supercomputing (via a Cerebras CS-2/WSE-2 strategic partnership) and a custom peptide synthesizer that closes the design-synthesize-test-train loop with proprietary data generation. Beyond PLG0206, Peptilogics has preclinical programs including PLG0301 for cystic fibrosis lung infections and AI-driven co-discovery collaborations with Orion Biotechnology (GPCR targets) and EpiAxis Therapeutics (epigenetic oncology).

Commercially, Peptilogics has no current revenue and is funded through equity and grant capital, most recently closing an oversubscribed $78 million Series B2 in October 2025 led by Presight Capital, Founders Fund, and Thiel Bio. Upon FDA approval, PLG0206 is expected to be distributed through U.S. hospital purchasing and specialty pharmacy channels targeting orthopedic and infectious disease departments. The company is led by founder/CEO Jonathan Steckbeck with a leadership team that combines anti-infective drug development, orthopedic device commercialization, HPC/AI, and large-pharma business development expertise.

Short descriptiontext

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using AI-driven design, with lead program PLG0206 in a pivotal Phase 2/3 trial for prosthetic joint infections — an indication with no approved therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, anti-biofilm drugs, AI drug discovery, prosthetic joint infection, computational peptide design
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Peptide Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Peptilogics is a clinical-stage biotechnology company with no current revenue. The company is developing peptide therapeutics for medical device-related infections with PLG0206 (zaloganan) in Phase 2/3 trials. Revenue will be generated through eventual commercialization of approved drug products.

peptilogics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using its proprietary Nautilus™ AI-powered computational design platform combined with purpose-built supercomputing. Its lead clinical asset, PLG0206 (zaloganan), is a first-in-class anti-biofilm engineered peptide therapeutic designed to cure and prevent medical device-related infections, specifically prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. The company is also advancing preclinical pipeline programs including PLG0301 for cystic fibrosis lung infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4-log10 mean bacterial reduction in explanted prosthetic joints exposed to PLG0206
+3 more records
Product overview1 text field

Peptilogics is a surgical therapeutics company advancing a novel anti-biofilm drug platform. The company's clinical stage pipeline is led by PLG0206 (also called zaloganan), a first-in-class engineered antimicrobial peptide therapeutic for treating prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. Supporting the therapeutic pipeline is the Nautilus™ AI platform, a computational drug discovery system that enables rapid peptide design and optimization through deep learning models and purpose-built supercomputing. The company also has preclinical programs including PLG0301 for cystic fibrosis lung infections.

Product and service2 records
1PLG0206 (Zaloganan)
CategoryAnti-infective peptide therapeutic (drug candidate)
Description

First-in-class engineered cationic antibacterial peptide therapeutic targeting and disrupting bacterial membranes within biofilms; designed to cure and prevent prosthetic joint infections (PJI) and other medical device-related infections. Has received FDA Orphan Drug Designation, Fast Track Designation, and Qualified Infectious Disease Product (QIDP) status. Currently enrolling Phase 2/3 RETAIN pivotal trial.

2Nautilus™ AI Discovery Platform
CategoryAI-driven computational drug discovery platform
Description

Proprietary AI-powered computational platform enabling in silico predictive peptide design across diverse targets. Combines deep generative models, predictive AI models, and biophysical simulation for multiparameter optimization of peptide sequences with drug-like properties (safety, efficacy, synthesizability, IP). Accelerated up to 1000x via purpose-built on-prem supercomputing and strategic Cerebras Systems partnership. Leveraged for internal pipeline and external co-discovery collaborations.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-08-15
Description

Strategic drug discovery partnership leveraging Peptilogics' AI platform for lead optimization against epigenetic oncology targets. Focus on reprogramming cancer cells and immune reinvigoration for metastatic breast cancer treatment.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-07-11
Description

AI-driven drug discovery collaboration targeting undrugged GPCR (G protein-coupled receptor) targets. Combines Peptilogics' Nautilus™ AI platform with Orion Biotechnology's proprietary receptor-ligand shape space exploration platform for precision-engineered peptides.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-08-18
Description

Strategic partnership leveraging Cerebras CS-2 system powered by the world's fastest AI processor (WSE-2) to accelerate peptide drug design. Peptilogics uses Cerebras' AI compute to run advanced deep learning models for novel peptide therapeutics discovery, potentially reducing training time by up to 1000x.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Computational drug discovery company using physics-based simulation and machine learning to design therapeutics, both for its own pipeline and through partnerships. Directly comparable to Peptilogics' AI-driven, in silico design approach to novel therapeutic candidates.

TypeBroad incumbent
Description

AI-powered antibody discovery platform company with a much larger partnership-driven business and broader biologic focus. Comparable in its use of AI/ML and high-throughput data infrastructure to accelerate biologic candidate generation, though focused on antibodies rather than antimicrobial peptides.

TypeDirect peer
Description

Clinical-stage peptide therapeutics company developing oral and injectable peptide candidates for endocrine diseases and rare conditions. Comparable in modality (synthetic peptides) and in using rational engineering to develop differentiated, drug-like peptide therapeutics.

TypeDirect peer
Description

Clinical- and commercial-stage peptide therapeutics company developing engineered peptides across metabolic and specialty indications. Comparable as a peptide-focused biotech using rational design to generate drug-like peptide candidates.

TypeEmerging player
Description

AI-native drug discovery company founded to apply frontier AI models to therapeutic discovery across multiple modalities and indications. Comparable as an emerging AI-driven biotech applying large-scale compute and generative models to expand addressable drug design space.

TypeEmerging player
Description

AI-driven drug discovery company using machine learning on large-scale biological data to identify novel therapeutics. Comparable in combining proprietary AI platforms with biological experimentation to discover differentiated drug candidates, though focused on small molecules and rare diseases.

TypeDirect peer
Description

Clinical-stage anti-infective company developing antibiotics (e.g., sulopenem) for drug-resistant infections including complicated urinary tract and intra-abdominal infections. Directly comparable as a small, focused anti-infective biotech pursuing regulatory differentiation against resistant pathogens.

TypeDirect peer
Description

Clinical-stage biopharma developing therapies with a focus on infectious disease and respiratory conditions, including antibiotic candidates. Comparable as a small-cap anti-infective biotech pursuing differentiated therapies against resistant pathogens.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable in its use of a proprietary computational platform to systematically generate drug candidates across multiple indications.

TypeDirect peer
Description

Was a clinical-stage anti-infective biotech developing direct lytic agents (lysins) and other novel therapies for drug-resistant bacterial infections. Comparable to Peptilogics in its focus on first-in-class anti-infective mechanisms targeting biofilm and resistant pathogens (though it has since undergone significant restructuring).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Peptilogics

Peptide Therapeuticspeptilogics.com

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using AI-driven design, with lead program PLG0206 in a pivotal Phase 2/3 trial for prosthetic joint infections — an indication with no approved therapeutics.

What Peptilogics does

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics for medical device-related infections, with its lead program PLG0206 (zaloganan) — a first-in-class engineered anti-biofilm peptide — currently enrolling patients in the pivotal Phase 2/3 RETAIN trial for the treatment of periprosthetic joint infection (PJI). The company targets an indication with no approved therapeutics, addressing approximately 45,000 U.S. cases annually where current standard-of-care failure rates reach 40–60% and five-year mortality is 25%. PLG0206 has secured a triple-layered FDA designation stack (Orphan Drug, Fast Track, and Qualified Infectious Disease Product), and the RETAIN trial is planned to enroll up to 240 patients across up to 50 U.S. clinical sites.

The company's discovery engine is the Nautilus™ AI platform, which combines proprietary deep generative models, predictive models, and biophysical simulation for in silico multiparameter optimization of peptide sequences. Nautilus™ is operationally paired with purpose-built supercomputing (via a Cerebras CS-2/WSE-2 strategic partnership) and a custom peptide synthesizer that closes the design-synthesize-test-train loop with proprietary data generation. Beyond PLG0206, Peptilogics has preclinical programs including PLG0301 for cystic fibrosis lung infections and AI-driven co-discovery collaborations with Orion Biotechnology (GPCR targets) and EpiAxis Therapeutics (epigenetic oncology).

Commercially, Peptilogics has no current revenue and is funded through equity and grant capital, most recently closing an oversubscribed $78 million Series B2 in October 2025 led by Presight Capital, Founders Fund, and Thiel Bio. Upon FDA approval, PLG0206 is expected to be distributed through U.S. hospital purchasing and specialty pharmacy channels targeting orthopedic and infectious disease departments. The company is led by founder/CEO Jonathan Steckbeck with a leadership team that combines anti-infective drug development, orthopedic device commercialization, HPC/AI, and large-pharma business development expertise.

Peptilogics firmographics

Firmographics
Name
Peptilogics
Legal name
Peptilogics, Inc.
Website
https://peptilogics.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using AI-driven design, with lead program PLG0206 in a pivotal Phase 2/3 trial for prosthetic joint infections — an indication with no approved therapeutics.
Ownership category
akta.pro rank

Peptilogics industry classification

Industry
Product category
Peptide Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Peptide therapeutics
  • Anti-biofilm drugs
  • AI drug discovery
  • Prosthetic joint infection
  • Computational peptide design

Where Peptilogics is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Peptilogics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Peptilogics is a clinical-stage biotechnology company with no current revenue. The company is developing peptide therapeutics for medical device-related infections with PLG0206 (zaloganan) in Phase 2/3 trials. Revenue will be generated through eventual commercialization of approved drug products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Peptilogics product offering

Product offering

Core offering

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using its proprietary Nautilus™ AI-powered computational design platform combined with purpose-built supercomputing. Its lead clinical asset, PLG0206 (zaloganan), is a first-in-class anti-biofilm engineered peptide therapeutic designed to cure and prevent medical device-related infections, specifically prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. The company is also advancing preclinical pipeline programs including PLG0301 for cystic fibrosis lung infections.

Product overview

Peptilogics is a surgical therapeutics company advancing a novel anti-biofilm drug platform. The company's clinical stage pipeline is led by PLG0206 (also called zaloganan), a first-in-class engineered antimicrobial peptide therapeutic for treating prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. Supporting the therapeutic pipeline is the Nautilus™ AI platform, a computational drug discovery system that enables rapid peptide design and optimization through deep learning models and purpose-built supercomputing. The company also has preclinical programs including PLG0301 for cystic fibrosis lung infections.

Differentiator

Problem solved

Functional benefit

Products and services

  • PLG0206 (Zaloganan) First-in-class engineered cationic antibacterial peptide therapeutic targeting and disrupting bacterial membranes within biofilms; designed to cure and prevent prosthetic joint infections (PJI) and other medical device-related infections. Has received FDA Orphan Drug Designation, Fast Track Designation, and Qualified Infectious Disease Product (QIDP) status. Currently enrolling Phase 2/3 RETAIN pivotal trial.
  • Nautilus™ AI Discovery Platform Proprietary AI-powered computational platform enabling in silico predictive peptide design across diverse targets. Combines deep generative models, predictive AI models, and biophysical simulation for multiparameter optimization of peptide sequences with drug-like properties (safety, efficacy, synthesizability, IP). Accelerated up to 1000x via purpose-built on-prem supercomputing and strategic Cerebras Systems partnership. Leveraged for internal pipeline and external co-discovery collaborations.

Quantifiable outcome

  • 4-log10 mean bacterial reduction in explanted prosthetic joints exposed to PLG0206
  • +3 more outcomes

Companies that use Peptilogics

Customer profile

Segments1 record

Ideal customer profiles2 records

Peptilogics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Peptilogics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic and core.

  • EpiAxis TherapeuticsstrategicStrategic or Co-development Partner · 15 August 2022Strategic drug discovery partnership leveraging Peptilogics' AI platform for lead optimization against epigenetic oncology targets. Focus on reprogramming cancer cells and immune reinvigoration for metastatic breast cancer treatment.
  • Orion BiotechnologystrategicStrategic or Co-development Partner · 11 July 2022AI-driven drug discovery collaboration targeting undrugged GPCR (G protein-coupled receptor) targets. Combines Peptilogics' Nautilus™ AI platform with Orion Biotechnology's proprietary receptor-ligand shape space exploration platform for precision-engineered peptides.
  • Cerebras SystemscoreTechnology or Integration · 18 August 2021Strategic partnership leveraging Cerebras CS-2 system powered by the world's fastest AI processor (WSE-2) to accelerate peptide drug design. Peptilogics uses Cerebras' AI compute to run advanced deep learning models for novel peptide therapeutics discovery, potentially reducing training time by up to 1000x.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Peptilogics competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Computational drug discovery company using physics-based simulation and machine learning to design therapeutics, both for its own pipeline and through partnerships. Directly comparable to Peptilogics' AI-driven, in silico design approach to novel therapeutic candidates.
  • Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company developing oral and injectable peptide candidates for endocrine diseases and rare conditions. Comparable in modality (synthetic peptides) and in using rational engineering to develop differentiated, drug-like peptide therapeutics.
  • Zealand Pharma: Clinical- and commercial-stage peptide therapeutics company developing engineered peptides across metabolic and specialty indications. Comparable as a peptide-focused biotech using rational design to generate drug-like peptide candidates.
  • Iterum Therapeutics: Clinical-stage anti-infective company developing antibiotics (e.g., sulopenem) for drug-resistant infections including complicated urinary tract and intra-abdominal infections. Directly comparable as a small, focused anti-infective biotech pursuing regulatory differentiation against resistant pathogens.
  • Theravance Biopharma: Clinical-stage biopharma developing therapies with a focus on infectious disease and respiratory conditions, including antibiotic candidates. Comparable as a small-cap anti-infective biotech pursuing differentiated therapies against resistant pathogens.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Comparable in its use of a proprietary computational platform to systematically generate drug candidates across multiple indications.
  • ContraFect Corporation: Was a clinical-stage anti-infective biotech developing direct lytic agents (lysins) and other novel therapies for drug-resistant bacterial infections. Comparable to Peptilogics in its focus on first-in-class anti-infective mechanisms targeting biofilm and resistant pathogens (though it has since undergone significant restructuring).

Broad incumbents

  • AbCellera Biologics: AI-powered antibody discovery platform company with a much larger partnership-driven business and broader biologic focus. Comparable in its use of AI/ML and high-throughput data infrastructure to accelerate biologic candidate generation, though focused on antibodies rather than antimicrobial peptides.

Emerging players

  • Xaira Therapeutics: AI-native drug discovery company founded to apply frontier AI models to therapeutic discovery across multiple modalities and indications. Comparable as an emerging AI-driven biotech applying large-scale compute and generative models to expand addressable drug design space.
  • Insitro: AI-driven drug discovery company using machine learning on large-scale biological data to identify novel therapeutics. Comparable in combining proprietary AI platforms with biological experimentation to discover differentiated drug candidates, though focused on small molecules and rare diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

Peptilogics social profiles

Digital presence

Peptilogics compliance and trust

Trust signal

Compliance2 records

Peptilogics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Peptilogics leadership team

Management profile

Number of profiles

Profiles14 records

Peptilogics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Peptilogics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peptilogics

What does Peptilogics do?

Peptilogics is a clinical-stage biotechnology company developing peptide-based therapeutics using its proprietary Nautilus™ AI-powered computational design platform combined with purpose-built supercomputing. Its lead clinical asset, PLG0206 (zaloganan), is a first-in-class anti-biofilm engineered peptide therapeutic designed to cure and prevent medical device-related infections, specifically prosthetic joint infections (PJI), currently enrolling the pivotal Phase 2/3 RETAIN trial. The company is also advancing preclinical pipeline programs including PLG0301 for cystic fibrosis lung infections.

Is Peptilogics a public or private company?

Peptilogics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Peptilogics founded?

Peptilogics was founded in 2013. It employs 11 to 50 people.

Where is Peptilogics based?

Peptilogics is headquartered in Pittsburgh, United States, in the North America region.

How does Peptilogics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Peptilogics's main competitors?

Direct peers on record are Schrödinger, Crinetics Pharmaceuticals, Zealand Pharma, Iterum Therapeutics, Theravance Biopharma, Recursion Pharmaceuticals and ContraFect Corporation. AbCellera Biologics is listed as a broad incumbent. Emerging players are Xaira Therapeutics and Insitro.

Does Peptilogics have an API?

No public API is recorded for Peptilogics.

What industry is Peptilogics in?

Peptilogics's product category is Peptide Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPeptilogics Enrolls First International Patient in Phase 2/3 RETAIN Trial of Zaloganan for Treatment of Prosthetic Joint InfectionPeptilogics announced the first international patient enrollment in the RETAIN Phase 2/3 trial of zaloganan for prosthetic joint infection, at Leeds Teaching Hospitals NHS Trust in the U.K. The trial plans to enroll about 240 patients across 50 sites in the U.S., U.K., and Australia, with a primary endpoint of treatment failure within 12 months.FinancialContent Business PagePeptilogics Enrolls First International Patient in Phase 2/3 RETAIN Trial of Zaloganan for Treatment of Prosthetic Joint InfectionPeptilogics announced the first international patient enrolled in the RETAIN Phase 2/3 trial of zaloganan for prosthetic joint infection at Leeds Teaching Hospitals NHS Trust in the U.K. The trial plans to enroll about 240 patients across 50 sites in the U.S., U.K., and Australia. Zaloganan is the first drug shown to penetrate biofilm and kill persister bacteria.Med-Tech InsightsFormer DePuy Synthes U.S. President joins Peptilogics boardTim Czartoski, former president of DePuy Synthes U.S. and Enovis, joined Peptilogics' board of directors. His experience leading orthopaedic device businesses, including robotic platforms and knee systems, is expected to support Peptilogics' commercialization of zaloganan for prosthetic joint infections.BastillepostFormer President of DePuy Synthes U.S. Joins Peptilogics BoardTim Czartoski, former president of DePuy Synthes U.S. and most recently of Enovis's U.S. Surgical division, has joined the board of directors at Peptilogics. This appointment aims to leverage Czartoski’s extensive commercial experience in orthopedic device launches to support Peptilogics' development of zaloganan, a drug candidate targeting prosthetic joint infections.citybizPeptilogics Adds Former DePuy Synthes U.S. President Tim Czartoski to BoardPeptilogics has appointed former DePuy Synthes U.S. President Tim Czartoski to its board of directors to support the development of its lead drug candidate, zaloganan. This appointment provides the company with significant commercial and orthopedic operating experience as zaloganan progresses through Phase 2/3 trials for treating prosthetic joint infections. The move aims to leverage Czartoski's background in launching major orthopedic products to help integrate the therapeutic into existing surgical workflows.FinancialContent Business PageFormer President of DePuy Synthes U.S. Joins Peptilogics BoardTim Czartoski, former president of DePuy Synthes U.S. and Enovis, has joined the board of directors at Peptilogics. This appointment supports Peptilogics' efforts to bring its drug candidate zaloganan to market for treating prosthetic joint infections. The move highlights a strategic shift in orthopedic surgery from purely device-based solutions to therapeutic treatments for device-related complications.Business Wire BlogFormer President of DePuy Synthes U.S. Joins Peptilogics BoardTim Czartoski, former president of DePuy Synthes U.S. and Enovis, has joined the board of directors at Peptilogics. This appointment aims to leverage his commercial experience in orthopedic device launches to support Peptilogics' development of zaloganan, a therapeutic drug for medical device-related infections. The move signals a strategic shift from purely surgical solutions to pharmacological treatments for prosthetic joint infections.UcUC enrolls first patients in clinical trial for prosthetic joint infectionsThe University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN clinical trial, which tests an investigational peptide solution for treating prosthetic joint infections. The trial aims to determine if this treatment can effectively penetrate biofilms and allow for infection management without the need for high-risk two-stage revision surgeries. If successful, the therapy could expand the treatment window beyond current limitations and reduce the failure rate associated with standard care.News-MedicalUniversity of Cincinnati launches clinical trial to test new drug for prosthetic joint infectionsThe University of Cincinnati enrolled two patients in a clinical trial testing a peptide solution for prosthetic joint infections. The trial, a randomized double-blind placebo-controlled study, will enroll 240 patients at up to 50 sites. If successful, it could avoid two-stage revision surgery and expand the treatment window beyond two weeks.Business Wire BlogPeptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related InfectionsPeptilogics has enrolled the first patient in the RETAIN Phase 2/3 registration trial for PLG0206, a first-in-class anti-biofilm drug designed to treat prosthetic joint infections. The multi-center study aims to evaluate the drug's efficacy against the current standard of care, targeting an unmet medical need with significant economic and health burdens. This milestone follows earlier Phase 1 studies that demonstrated the safety profile and preliminary efficacy of the candidate.